For the quarter ending 2025-09-30, SPRY has $372,803K in assets. $225,148K in debts. $59,557K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 59,557 | 51,540 | ||
| Short-term investments | 228,652 | 188,590 | ||
| Accounts receivable, net | 36,451 | 25,126 | ||
| Inventories | 7,782 | 8,738 | ||
| Prepaid expenses and other current assets | 6,421 | 7,442 | ||
| Total current assets | 338,863 | 281,436 | ||
| Long-term inventories | 13,645 | 13,374 | ||
| Right-of-use asset | 1,439 | 1,564 | ||
| Fixed assets, net | 1,209 | 1,075 | ||
| Intangible assets, net | 14,729 | 12,972 | ||
| Other assets | 2,918 | 3,051 | ||
| Total assets | 372,803 | 313,472 | ||
| Accounts payable and accrued liabilities (including related party amounts of 4,458 and 656, respectively) | 49,768 | 44,264 | ||
| Contract liability, current | 526 | 746 | ||
| Lease liability, current | 583 | 589 | ||
| Total current liabilities | 50,877 | 45,599 | ||
| Term loans, net (including related party amounts of 4,811 and 0, respectively) | 96,229 | - | ||
| Financing liability | 72,044 | 71,959 | ||
| Contract liability, net of current portion | 1,268 | 1,103 | ||
| Lease liability, net of current portion | 949 | 1,072 | ||
| Other accrued liabilities | 3,781 | 1,418 | ||
| Total liabilities | 225,148 | 121,151 | ||
| Common stock, 0.0001 par value per share 200,000,000 shares authorized at september 30, 2025 and december 31, 2024 98,844,178 and 97,954,172 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 10 | 10 | ||
| Additionalpaid-incapital | 400,931 | 394,485 | ||
| Accumulated other comprehensive (loss) gain, net | -7 | -46 | ||
| Accumulated deficit | -253,279 | -202,128 | ||
| Total stockholders' equity | 147,655 | 192,321 | ||
| Total liabilities and stockholders' equity | 372,803 | 313,472 | ||
ARS Pharmaceuticals, Inc. (SPRY)
ARS Pharmaceuticals, Inc. (SPRY)